“Kemwell’s oral care unit (OCU) will provide services such as formulation development, stability studies and the manufacture of clinical trial materials.” Oral consumer goods such as Sensodyne toothpaste are an example of some of the products of focus along with pursuing filling the pipeline with new consumer related items. BD
The facility, in Bangalore, will serve the R&D needs of GSK Consumer Healthcare, which remains a key focus for the pharmaceutical major under recently-appointed CEO Andrew Witty, despite repeated calls for the sale of the division, which makes oral care products such as toothpastes and mouthwashes as well as over0the-counter medicines. GSK has committed to reducing the risks in its business, with a strategy predicated on a more diversified product portfolio spanning small-molecule and biologics medicines, over-the-counter pharmaceuticals and personal care products, with a global focus that taps into emerging markets such as Asia, Latin America and Africa.
But the latest deal with Kemwell indicates that GSK is also committed to R&D in the consumer health arena. It also represents a step-up in the degree of collaboration between GSK and Kemwell, which has been manufacturing various products for the drug major for the last 10 years.